October 2020 in “Revista médica sinergía/Revista médica sinergia” Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
3 citations
,
February 2025 in “Journal of Dermatological Treatment” Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
2 citations
,
July 2024 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” No treatment works for everyone, and emotional support is crucial.
January 2022 in “Clinical Cases in Dermatology” A 22-year-old man has alopecia areata, an autoimmune hair loss condition, with various treatments available.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
10 citations
,
August 2022 in “International Journal of Molecular Sciences” Leptin-deficient mice, used as a model for Type 2 Diabetes, have delayed wound healing due to impaired contraction and other dysfunctional cellular responses.
47 citations
,
October 2014 in “Expert Opinion on Emerging Drugs” New alopecia treatments aim for better results and fewer side effects.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
July 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Assessing CD8+ T cell levels before surgery may improve vitiligo treatment outcomes.
June 2021 in “Aesthetic Cosmetology and Medicine” Some people lose a lot of hair after having COVID-19.
32 citations
,
April 2016 in “Journal of Investigative Dermatology” STAT5 activation is crucial for starting the hair growth phase.
78 citations
,
October 2020 in “Experimental Dermatology” Hidradenitis suppurativa is caused by genetic factors, inflammation, bacteria, hormones, and lifestyle factors like obesity and smoking.
52 citations
,
September 2022 in “Viruses” SARS-CoV-2 proteins help the virus avoid the immune system, delaying response and increasing inflammation.
52 citations
,
January 2021 in “Journal of Thoracic Oncology” Effective vaccines and treatments are crucial for long-term COVID-19 control.
47 citations
,
December 2019 in “Frontiers in immunology” A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
27 citations
,
July 2017 in “European Journal of Dermatology” Certain microRNAs are linked to various skin diseases and could be used to diagnose and treat these conditions.
11 citations
,
July 2016 in “Endocrinology” Higher Lnk protein levels in ovaries may lead to insulin resistance in women with PCOS.
7 citations
,
March 2024 in “Skin Research and Technology” miR-200c-3p could help diagnose and treat alopecia areata.
1 citations
,
January 2026 in “Dermatology Reports” Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.
1 citations
,
March 2025 in “JAAD reviews.” Significant progress has been made in treating skin, hair, and nail disorders in people with skin of color, but disparities still exist.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
January 2026 in “Non-coding RNA Research” Exosomal miRNA-218-5p promotes hair growth and development.
January 2024 in “Archives of dermatological research” Both treatments for alopecia areata showed similar modest effectiveness.
July 2022 in “Research Square (Research Square)” Certain miRNAs may play a role in sheep hair follicle development, which could help improve wool production.
May 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The study found that certain genes are important for hedgehog skin appendage development and immunity, with spines possibly evolving for protection and infection resistance.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” HDAC inhibitors, like Vorinostat and Entinostat, can help regrow hair in alopecia areata.